---
title: "DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune"
description: "Faruqi & Faruqi, LLP is investigating claims on behalf of investors who suffered losses exceeding $75,000 in Altimmune, Inc. between August 10, 2023, and June 25, 2025. Investors are encouraged to con"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251882441.md"
published_at: "2025-08-06T17:39:54.000Z"
---

# DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

> Faruqi & Faruqi, LLP is investigating claims on behalf of investors who suffered losses exceeding $75,000 in Altimmune, Inc. between August 10, 2023, and June 25, 2025. Investors are encouraged to contact partner Josh Wilson regarding their legal rights before the October 6, 2025 deadline to seek lead plaintiff status in a federal securities class action. Following disappointing trial results, Altimmune's stock price plummeted by 53.2% in one day, from $7.71 to $3.61 per share. The firm invites anyone with information about Altimmune's conduct to reach out.

Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimmune To Contact Him Directly To Discuss Their Options.

### Related Stocks

- [ALT.US - Altimmune](https://longbridge.com/en/quote/ALT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Altimmune 董事 Wayne Pisano 购入普通股 | 韦恩·皮萨诺（Wayne Pisano），Altimmune Inc. 的董事，已购买该公司的普通股。完整的文件可通过提供的链接获取。此消息由公共技术公司生成，仅供参考，不应被视为财务、投资或法律建议。Altimmune Inc. 对于 2 | [Link](https://longbridge.com/en/news/272122963.md) |
| Altimmune 公司董事 Catherine A. Sohn 报告了普通股的收购 | Catherine A. Sohn，Altimmune Inc. 的董事，已报告收购该公司的普通股。完整的文件可通过提供的链接获取。此新闻简报由公共技术公司生成，仅供信息参考，不应被视为财务、投资或法律建议。Altimmune Inc. 对 | [Link](https://longbridge.com/en/news/271563101.md) |
| Altimmune 公司获得 FDA 突破性疗法认定，用于 Pemvidutide 治疗 MASH | Altimmune Inc. 已获得美国食品药品监督管理局（FDA）对 pemvidutide 的突破性疗法认定，这是一种用于治疗代谢功能障碍相关脂肪肝炎（MASH）的双受体激动剂。该认定是在 IMPACT 2b 期临床试验取得积极结果后获 | [Link](https://longbridge.com/en/news/271512829.md) |
| Altimmune 董事 Diane Jorkasky 收购普通股 | Diane Jorkasky，Altimmune Inc. 的董事，已购买该公司的普通股。完整的文件可通过提供的链接获取。此消息由公共技术公司生成，仅供信息参考，不应被视为财务或法律建议。Altimmune Inc. 对于 2025 年 1 | [Link](https://longbridge.com/en/news/271030324.md) |
| Altimmune 董事 John Gill 报告了普通股的收购 | Altimmune Inc. 的董事 John Gill 已经收购了该公司的普通股。此事件通过美国证券交易委员会的 EDGAR 系统进行了备案。该信息由 Altimmune Inc. 于 2025 年 12 月 23 日发布，仅供参考 | [Link](https://longbridge.com/en/news/270655085.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
